JPMorgan Chase & Co. raised its position in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 31.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,955,279 shares of the company’s stock after purchasing an additional 698,701 shares during the period. JPMorgan Chase & Co. owned about 5.23% of ARK Genomic Revolution ETF worth $75,655,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also made changes to their positions in the company. Chris Bulman Inc bought a new position in ARK Genomic Revolution ETF in the second quarter worth approximately $36,000. Larson Financial Group LLC lifted its stake in shares of ARK Genomic Revolution ETF by 4,576.1% during the 2nd quarter. Larson Financial Group LLC now owns 3,320 shares of the company’s stock worth $78,000 after purchasing an additional 3,249 shares during the last quarter. National Bank of Canada FI grew its stake in ARK Genomic Revolution ETF by 28.4% in the third quarter. National Bank of Canada FI now owns 4,155 shares of the company’s stock valued at $106,000 after purchasing an additional 920 shares during the last quarter. IHT Wealth Management LLC bought a new position in ARK Genomic Revolution ETF in the third quarter worth about $203,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of ARK Genomic Revolution ETF in the 2nd quarter valued at about $222,000.
ARK Genomic Revolution ETF Price Performance
BATS:ARKG opened at $25.68 on Friday. The company’s 50 day moving average price is $24.67 and its 200 day moving average price is $24.96.
ARK Genomic Revolution ETF Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Further Reading
- Five stocks we like better than ARK Genomic Revolution ETF
- What is the Nikkei 225 index?
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- Consumer Staples Stocks, Explained
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.